

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

Am

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/71	A1	(11) International Publication Number: WO 00/03722 (43) International Publication Date: 27 January 2000 (27.01.00)
(21) International Application Number: PCT/US99/15776 (22) International Filing Date: 13 July 1999 (13.07.99) (30) Priority Data: 60/093,021 16 July 1998 (16.07.98) US 60/108,716 17 November 1998 (17.11.98) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US). (72) Inventors: LEET, John, E.; 40 Granby Drive, Madison, CT 06443 (US). AX, Helen, A.; 16 Centre Village Drive, Madison, CT 06443 (US). GUSTAVSON, Donald, R.; 413 Clearview Avenue, Torrington, CT 06790 (US). BROWN, Daniel, M.; 231 Chestnut Hill Road, Killingworth, CT 06419 (US). TURNER, Laura; 49 Holmes Street, Mystic, CT 06355 (US). BROWN, Kimberly; 109 Ross Road, Rockfall, CT 06481 (US). LI, Wenying; 6221 Town Place, Middletown, CT 06457 (US). LAM, Kin, S.; 33 Sara Circle, North Haven, CT 06473 (US). (74) Agent: DUBOFF, Samuel, J.; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NOCATHIACIN ANTIBIOTICS (57) Abstract Novel thiazolyl peptide antibiotic compounds, including nocathiacin I, II and III, are disclosed. Also, novel microorganism ATCC-202099 is disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Kazakstan	RO	Romania		
CU	Cuba	KZ	Kazakstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

NOCATHIACIN ANTIBIOTICS

BACKGROUND

5

The emergence of bacterial resistance to a number of antimicrobial agents such as beta-lactam antibiotics, macrolides, quinolones, and vancomycin is becoming a major worldwide health problem. (Cohen, M. L. Antimicrobial resistance: prognosis for public health. *Trends Microbiol.* 10 1994, 2, 422-425). The most significant problem in clinical practice is the increase in incidence of methicillin-resistant *Staphylococcus aureus* (MRSA) strains. At present, the only effective treatment for multiple resistant MRSA infections is vancomycin. However, there are recent reports of emerging vancomycin resistance in some MRSA isolates. 15 Another group of clinically relevant multiple drug resistant bacteria that have emerged recently are the *Enterococci*. The emerging resistance of the important community acquired pathogen *Streptococcus pneumoniae* to penicillin and other antibacterials is also becoming a worldwide health problem. Multi drug-resistant strains of *Mycobacterium tuberculosis* 20 have surfaced in several countries including the United States. The emergence and spread of resistant nosocomial and community-acquired pathogens is generating a great threat to public health worldwide. There is an urgent need to discover new agents to treat patients infected with multidrug-resistant bacteria. The present invention addresses this need.

25

New thiazolyl peptide antibiotics, (designated herein as nocathiacin I, II and III, or collectively as nocathiacin) having inhibitory activity at the nanomolar level against Gram-positive bacteria (e.g. multiple drug resistant *Enterococcus faecium*), are described. The novel antibiotics 30 described herein were isolated from cultured broth of *Nocardia* sp. ATCC-202099. Known members of the thiazolyl peptide class of antibiotics such as thiostrepton and nosiheptide, and glycothiohexide- α have been reported to exhibit potent antimicrobial activity against Gram-positive

bacteria *in vitro*, with no reported activity *in vivo*. The novel antibiotics disclosed herein exhibit *in vivo* efficacy in a systemic *Staph. aureus* infection model in mice.

5 Nocathiacin I has been previously described by J. E. Leet *et al* (U.S. Provisional Patent Application Serial No. 60/093,021 filed July 16, 1998) commonly owned by Applicant herein, and Sasaki, T. *et al*, *J. of Antibiotics* 51, No. 8, pp. 715-721 (published August 25, 1998). The novel
10 nocathiacin antibiotics of this invention are related to but clearly distinguishable from nosiheptide (Prange T. *et al.*, *J. Am Chem Soc.* 99, 6418 (1977); Benazet, F. *et. al. Experientia* 36, 414 (1980); Floss, H. G. *et al.*, *J. Am Chem Soc.* 115, 7557 (1993); glycothiohexides (Steinberg, D.A. *et al*, *J. Antibiot.* 47, 887 (1994); M. D. Lee *et al*, *J. Antibiot.* 47, 894 (1994); M. D. Lee *et al*, *J. Antibiot.* 47, 901 (1994); U. S. Patent No. 5,451,581, 1995), and
15 Antibiotic S-54832A (U. S. Patent No. 4,478,831, 1984).

SUMMARY OF THE INVENTION

20 The invention concerns novel thiazolyl peptide antibiotic compounds nocathiacin I, II and III. The antibiotics of this invention can be isolated and purified from *Nocardia sp.* (strain WW-12651, ATCC-202099) fermentation broths.

25 The invention also deals with pharmaceutical compositions and methods for treating bacterial infections with nocathiacin I, II and III antibiotics, as well as a biologically pure culture of *Nocardia sp.* strains from which the antibiotics are obtained. The invention includes all pharmaceutically acceptable derivatives of nocathiacin antibiotics, such as
30 pharmaceutically acceptable salts and esters thereof.

The utility of the subject compound in the treatment of bacterial infections is based upon the expectation that compounds which inhibit Gram-positive bacteria *in vitro* and *in vivo* can be used as antibiotics in mammals, and in particular, humans. The compounds of this invention
5 were found to have antibiotic activity, particularly in inhibiting the growth of Gram-positive bacteria.

DESCRIPTION OF THE DRAWINGS

10

Figure 1 shows the ultraviolet absorption (UV) spectrum of nocathiacin I.

Figure 2 shows the infrared absorption (IR) spectrum of nocathiacin I.

15 Figure 3 shows the ^1H -NMR spectrum (500 MHz) of nocathiacin I in deuterated dimethylsulfoxide.

Figure 4 shows the ^{13}C -NMR (125 MHz) spectrum of nocathiacin I in deuterated dimethylsulfoxide.

20

Figure 5 shows the ultraviolet absorption (UV) spectrum of nocathiacin II.

Figure 6 shows the infrared absorption (IR) spectrum of nocathiacin II.

25 Figure 7 shows the ^1H -NMR spectrum (500 MHz) of nocathiacin II in deuterated dimethylsulfoxide.

Figure 8 shows the ^{13}C -NMR (125 MHz) spectrum of nocathiacin II in deuterated dimethylsulfoxide.

30

Figure 9 shows the ultraviolet absorption (UV) spectrum of nocathiacin III.

Figure 10 shows the infrared absorption (IR) spectrum of nocathiacin III.

Figure 11 shows the ^1H -NMR spectrum (500 MHz) of nocathiacin III in deuterated dimethylsulfoxide.

5

Figure 12 shows the ^{13}C -NMR (125 MHz) spectrum of nocathiacin III in deuterated dimethylsulfoxide.

10

DETAILED DESCRIPTION OF THE INVENTION

The antibiotic compounds called nocathiacin I, II and III were discovered in a program designed to find novel compounds produced by fermentation. The subject nocathiacin compounds were isolated from a
15 cultured fermentation broth of *Nocardia* sp. strain WW-12651 (ATCC-202099), and were purified by extraction and chromatographic procedures to yield solids of amorphous character.

Description of the Microorganism

20

The microorganism which may be used for the production of nocathiacin antibiotics is a strain of *Nocardia* sp. isolated from a soil sample collected in New Mexico. The culture (strain WW-12651) was deposited on March 4, 1998 with the American Type Culture Collection
25 (ATCC) in Rockville, MD, with the accession number of ATCC-202099. The ATCC deposit meets all of the requirements of the Budapest treaty. The dormant culture is also maintained at the Bristol-Myers Squibb Pharmaceutical Research Institute Culture Collection at 5 Research Parkway, Wallingford, CT 06492. In addition to the specific
30 microorganism described herein, it should be understood that mutants, such as those produced by the use of chemical or physical mutagens including X-rays, etc. and organisms whose genetic makeup has been

modified by molecular biology techniques, may also be cultivated to produce nocathiacin antibiotics.

Microscopic studies on strain WW-12651 were carried out on ISP morphology media (ISP2, ISP3, ISP4, ISP5, and ISP7) and observations were made at 7, 14, and 21 days of incubation at 28°C according to the International Streptomyces Project manual recommendations.

Growth on ISP4 medium develops as yellow cream colored colonies. The aerial mycelium is white and fragments extensively. Under light microscopy, spore chains are observed in the vegetative mycelium while few to no spore chains are seen in the cob web-like mycelium. The observed morphology classifies this organism as a non-*Streptomyces* type. A light brown-orange reverse color is observed on salts-starch agar (ISP4). There were no diffusible pigments produced on any of the ISP media. Melanoid pigments are not formed on tyrosine agar (ISP7) and are not detected by the modified Arai and Mikami melanin formation test.

The amino acid components of the cell wall are alanine, L-glutamic acid, aspartic acid, and the meso-diaminopimelic acid isomer. The sugar components of the cell wall are galactose, arabinose, and ribose. Carbon utilization studies showed that glucose, mannitol, sucrose, xylose and fructose (weak) were utilized for growth when incorporated into inorganic salts agar (ISP9) as sole carbon sources. Arabinose, inositol, raffinose, and rhamnose were not utilized for growth as sole carbon sources with ISP9. Based on the above characteristics and analysis of mycolic acids, this organism has been characterized as a member of the genus *Nocardia*.

Fermentation of *Nocardia* sp. (strain WW-12651)

The production of nocathiacin antibiotics may be carried out by cultivating *Nocardia* sp. (strain WW-12651) in a suitable nutrient medium under conditions described herein, preferably under submerged aerobic conditions, until a substantial amount of nocathiacins are detected in the fermentation, harvesting by extracting the active components from the mycelial growth with a suitable solvent, concentrating the solution containing the desired components, then subjecting the concentrated material to chromatographic separation to isolate the compounds from other metabolites also present in the cultivation medium.

Production of nocathiacin can be effected at temperature conducive to satisfactory growth of the producing organism, e.g. 16 °C and 40 °C, but it is preferable to conduct the fermentation at 22 °C to 32 °C. The aqueous medium is incubated for a period of time necessary to complete the production of nocathiacin as monitored by high pressure liquid chromatography (HPLC) usually for a period of about 1-6 days, on a rotary shaker operating at about 50 rpm to 300 rpm, preferably at 150 rpm to 250 rpm.

Growth of the microorganisms may be achieved by one of ordinary skill of the art by the use of appropriate medium. Broadly, the sources of carbon include glucose, fructose, mannose, maltose, galactose, mannitol and glycerol, other sugars and sugar alcohols, starches and other carbohydrates, or carbohydrate derivatives such as dextran, cerelese, as well as complex nutrients such as oat flour, corn meal, millet, corn and the like. The exact quantity of the carbon source which is utilized in the medium will depend in part, upon the other ingredients in the medium, but it is usually found that an amount of carbohydrate between 0.5 to 10 percent by weight of the medium is satisfactory. These carbon sources can

be used individually or several such carbon sources may be combined in the same medium. Certain carbon sources are preferred as hereinafter set forth.

5 The sources of nitrogen include amino acids such as glycine, arginine, threonine, methionine and the like, ammonium salt, as well as complex sources such as yeast extracts, corn steep liquors, distiller solubles, soybean meal, cottonseed meal, fish meal, and the like. The various sources of nitrogen can be used alone or in combination in amounts
10 ranging from 0.05 to 5 percent by weight of the medium.

 Among the nutrient inorganic salts, which can be incorporated in the culture media, are the customary salts capable of yielding sodium, potassium, magnesium, calcium, phosphate, sulfate, chloride, carbonate,
15 and like ions. Also included are trace metals such as cobalt, manganese, iron, molybdenum, zinc, cadmium, and the like.

 Typically, *Nocardia* sp. (strain WW-12651) was grown in a 500 ml flask containing 100 ml of vegetative medium consisting of the following
20 per liter of deionized water: starch, 20g; dextrose, 5g; N-Z case, 3g; yeast extract, 2g; fish meat extract, 5g; calcium carbonate, 3g. The culture was allowed to incubate for 3 days at 32°C on a rotary shaker operating at 250 rpm. The vegetative culture was mixed with equal volume of cryoprotective solution consisting of 100 g sucrose and 200 g glycerol per
25 liter of deionized water. Four ml portions of this mixture were transferred to sterile cryogenic tube (5 ml capacity) and were frozen in a dry ice-acetone bath. The frozen vegetative cultures so obtained were then stored at -80°C.

30 Seed culture for the production of nocathiacin antibiotics was prepared by transferring 4 ml of the cryopreservative culture to a 500 ml

flask containing 100 ml of sterile vegetative medium having the same composition as the above. The seed culture was incubated at 28 °C to 32 °C for 3 days on a rotary shaker operating at 250 rpm. Four ml of this seed culture was inoculated into 500 ml flask containing 100 ml of production medium consisting of the following per liter of deionized water: HY Yest 412, 10g; glucose, 20g; Nutrisoy, 10g. This is the preferred production medium. The production culture was incubated at 24 °C to 32 °C on a rotary shaker operating at 180 rpm to 250 rpm. Optimal production of nocathiacin antibiotics was generally obtained at 4-5 days of fermentation.

10

When the nocathiacin I, II or III compounds are employed as pharmaceutical compositions for the treatment of bacterial infections, they may be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

25

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to

30

four times a day, or in sustained release form. For most large mammals the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

10

These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

30

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

10

The term pharmaceutically acceptable salt includes solvates, hydrates, acid addition salts and quaternary salts. The acid addition salts are formed from a nocathiacin I, II or III compound having a basic nitrogen and a pharmaceutically acceptable inorganic or organic acid including but not limited to hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, citric, malonic, succinic, fumaric, maleic, sulfamic, or tartaric acids. Quaternary salts are formed from a basic nocathiacin I, II or III compound and an alkyl or arylalkyl halide, preferably methyl or benzyl bromide.

20

It is understood that the nocathiacin compounds of the invention herein include the various stereoisomers that may exist.

Description of the MREF assay procedures

25

The biological activity of the nocathiacin antibiotic compounds was discovered when a crude extract prepared from the producing *Nocardia* sp. (ATCC 202099) culture was tested in a high throughput screening assay. The screen is based on growth inhibition of *Enterococcus faecium* strain A28152 inoculated into agar growth media. This *E. faecium* strain is resistant to many antibiotics, including penicillin G, vancomycin,

30

ciprofloxacin, teicoplanin, tetracycline, streptomycin, gentamicin, erythromycin, clindamycin and rifampin. It is sensitive to chloramphenicol and, to a lesser extent, imipenem. Hence the name MREF, which stands for Multi-drug Resistant *E. faecium*.

5

E. faecium strain A28152 is inoculated into Brain Heart Infusion Broth nutrient medium and cultured to log phase growth by incubation at 37° C with agitation. Periodically, 0.2 mL aliquots of culture are withdrawn and pipetted into a well in a 96 well clear plastic flat-bottom plate. The optical density at 595 nm is then measured. When the optical density is in the range of 0.2 to 0.4, the bacteria are harvested by centrifugation at 1000 x g for 10 minutes. The cell pellet is resuspended in Mueller-Hinton II growth media. This suspension of cells is then inoculated into molten Mueller-Hinton II growth media containing 1% Difco agar at a temperature of 48° C, to give an inoculated cell density of 1 x 10⁷ cells/mL. 25 mL of the cell suspension is poured into a sterile rectangular plate. A special sterile plastic lid that mates with the plate is placed on top of the plate while the media is still molten. This lid contains plastic pegs arranged in the standard 8 x 12 format. The media is allowed to gel at room temperature for 15 minutes, then the pin lid is removed. Small concave impressions remain in the gelled media where the pins contacted the surface of the molten media. These serve as sample loading zones.

25 Samples to be tested in the screen are dissolved to a concentration of 300 µM in 100% dimethylsulfoxide (DMSO). A 6 µL volume of each sample is applied to individual sample loading zones on the plate. After sample loading, the plate is incubated at 37° C for 24 hours. Growth inhibition is detected as a clear circular zone surrounding the sample zone. Outside of this zone, where the bacterial growth is unimpeded, the agar medium is turbid due to bacterial growth. DMSO alone does not

30

cause any detectable growth inhibition under these conditions. Samples of chloramphenicol and DMSO are included on each plate as positive and negative controls, respectively.

5 For Thin Layer Chromotography (TLC) biograms for use in identifying the active principal(s) present in the producing *Nocardia* sp. (ATCC 202099) culture, the materials used included Bio-Assay Dishes from Nunc Nalge International used for agar diffusion assays. The dish measures 243x243x18mm and provides a 530 cm² microbiological culture
10 area. The TLC plate is attached to the bio-assay dish and then an agar overlay is poured slowly covering the entire TLC plate and the bottom of the bio-assay dish. The agar overlay consists of 200 mL Mueller-Hinton II agar medium supplemented with 0.5% defibrinated sheep's blood and 1x10⁶ cells/mL of strain A28152, the drug-resistant *Enterococcus faecium*
15 strain. Once cool, the TLC biogram is incubated at room temperature for approximately 18 hours. After incubation, the blood agar turns a reddish-brown color due to the α -hemolytic activity of this *Enterococcus* strain. If a compound inhibits the growth of this strain, a localized highly visible red zone results due to inhibition of hemolysis. This procedure allows for
20 correlation of the desired biological activity with the appropriate chromatographic fractions, which in turn accelerates the identification of active principals and their isolation.


Adapting this procedure for use with the MREF assay involved
25 testing of two different contrast agents. The first was 2,3, 5-triphenyl-2H-tetrazolium chloride OR (0.003% final) supplemented to 200 mL of Todd Hewitt agar medium. The second was the 0.5% sheep's blood supplemented to 200 mL of Mueller-Hinton agar medium. Both procedures showed definitive zones of growth inhibition, but the
30 resolution was better and the incubation time was shorter with the blood


agar medium. A range of cell inoculums were tested but 1×10^6 cells/ml gave the best results.

Isolation and structural characterization

5

The purification of nocathiacin antibiotics from *Nocardia* sp. fermentations was monitored using a multiple drug resistant *Enterococcus faecium* (MREF) agar diffusion assay. Extraction with ethyl acetate, followed by solvent partitioning, Sephadex LH-20 and/or silica gel
10 chromatography were carried out. These steps yielded a complex of nocathiacin antibiotics which showed activity in the MREF agar diffusion assay. Final purification of the individual nocathiacin antibiotics was accomplished by normal or reverse phase preparative HPLC. Spectral data
15 indicated that the compounds are in the thiazolyl peptide class of antibiotics. The structures of nocathiacin I, II and III (shown below) were assigned based on 2D NMR studies and positive ion electrospray HRMS and MS/MS data.



wherein W is  and R is OH (for nocathiacin I) or R is H (for nocathiacin II); and W is H and R is OH (for nocathiacin III).

General Methods:

5

Materials:

Hexanes, chloroform, (anhydrous ACS grade), and methanol, acetonitrile (anhydrous HPLC grade) were obtained from the Fisher Scientific Company. These solvents were not repurified or redistilled. Water used in chromatography experiments refers to in-house deionized water passed through a Millipore 4 cartridge reagent grade water system (10 mega ohm Milli-Q water). Sephadex LH-20 was from Pharmacia LKB, Uppsala, Sweden. Dicalite (diatomaceous earth) was manufactured by Grefco Minerals, Torrance, CA. LiChroprep Si 60, 25-40 μm was from EM Separations, NJ, a U.S. associate of E. Merck, Germany.

Analytical Thin Layer Chromatography (TLC):

Uniplate Silica Gel GHF precoated thin layer chromatography plates (scored 10 x 20 cm, 250 microns) were purchased from Analtech, Inc., Newark, DE. Fractions were spotted using size 2 microliter Microcaps (disposable pipets) and the plates were developed in a tank equilibrated with chloroform-methanol (9:1 v/v). The components of the resulting chromatogram were visualized by long wavelength UV light and/or ceric sulfate-sulfuric acid spray reagent followed by prolonged heating.

Analytical HPLC:

The purification of the nocathiacin antibiotics was monitored by HPLC analysis on an APEX 5 μ ODS column, 4.6 mm i.d. x 15 cm l. (product of Jones Chromatography Inc., Lakewood, CO). Analyses were done on a Hewlett Packard 1100 Series Liquid Chromatograph, with UV detection at 254 nm. A gradient system of acetonitrile and 0.01M potassium phosphate buffer pH 3.5 was used, according to the method of D.J. Hook et.al. (*J. Chromatogr.* 385, 99 (1987). The eluant was pumped at a flowrate of 1.2 ml/min.

Preparative HPLC:

The following components were used to construct a preparative HPLC system: Beckman Instruments Inc. (Somerset, NJ), Beckman "System Gold" 126 Programmable Solvent Module; Beckman 166 Programmable Detector Module; Beckman "System Gold" Version 711U software; IBM PS/2 55SX System Controller; YMC Inc. (Wilmington, NC) Preparative HPLC column (normal phase): PVA-Sil 5 μ particle size, 120 Å pore size, 20 mm i.d. x 150 mm l., fitted with a Diol 25 μ particle size, 120 Å pore size, 10 mm i.d. x 10 mm l. drop-in guard module); mobile phase chloroform - methanol gradient, flow rate 10 ml/min. UV detection: 290 nm. Alternative column (reverse phase): YMC Inc. ODS-AQ 5 μ particle size, 120 Å pore size, 20 mm i.d. x 150 mm l., fitted with a ODS-A 25 μ particle size, 120 Å pore size, 10 mm i.d. x 10 mm l. drop-in guard module); mobile phase 0.1M ammonium acetate - acetonitrile gradient; flow rate 10 ml/min. UV detection: 360 nm.

Analytical Instrumentation

Low resolution MS measurements were performed with a Finnigan SSQ 7000 single quadrupole mass spectrometer, using the positive electrospray ionization mode. MS/MS measurements were conducted in the positive electrospray ionization mode with a Finnigan TSQ 7000 tandem quadrupole mass spectrometer using Argon collision gas or a Finnigan LCQ ion trap mass spectrometer. High resolution MS data were determined with a Finnigan MAT 900 magnetic sector mass spectrometer, positive electrospray ionization mode, ppg reference. The UV spectra were obtained using a Hewlett-Packard 8452A diode array spectrophotometer. IR measurements were taken on a Perkin Elmer 2000 Fourier Transform spectrometer. ^1H -NMR and ^{13}C -NMR spectra were obtained on a Bruker DRX-500 instrument operating at 500.13 and 125.76 MHz, respectively, using a Nalorac microprobe. Chemical shifts are reported in parts per million (ppm) relative to solvent (DMSO-d_6 , δ_{H} 2.49; δ_{C} 39.6). CD data were recorded with a Jasco J-720 spectropolarimeter.

EXAMPLES

The following examples set out the preparation of nocathiacin antibiotics and their biological properties. Reasonable variations, such as those which would occur to a skilled artisan can be made herein without departing from the scope of the invention.

FERMENTATION AND PURIFICATION OF NOCATHIACIN I & II

Nocathiacin I & II Preparation by Fermentation:

- 5 From the frozen vegetative stock culture of *Nocardia* sp. ATCC 202099, 4 ml was used to inoculate 100 ml of seed medium containing the following per liter of deionized water: starch, 20 g; Dextrose, 5 g; N-Z case, 3g; yeast extract, 2g; fish meat extract, 5g; calcium carbonate, 3g, in a 500-ml flask. The culture was incubated at 32 °C on a rotary shaker
- 10 operating at 250 rpm for 3 days., Four ml of the resulting culture was used to inoculate each of two hundred 500-ml flasks containing 100 ml of production medium consisting of the following per liter of deionized water: Dextrose, 20 g; peptone, 5 g; Red Star yeast, 10g; Allophosite, 5g. The production cultures were incubated at 32 °C on a rotary shaker
- 15 operating at 250 rpm for 5 days. The cultures were then processed for the recovery of nocathiacin I & II.

EXAMPLE 1: From Fermentation in Shake Flasks

20 Preparation of Crude Extract A:

- Fermentation broth of *Nocardia* sp. ATCC-202099 (20 L.) was extracted (whole broth including mycelia) with approximately 8 L. ethyl acetate by vigorous stirring for 1/2 hour. The biphasic mixture was mixed
- 25 with approximately 3 L. (1 Kg) of dicalite and filtered by vacuum filtration using a large Coors Buchner funnel (27 cm i.d., 28.5 cm o.d., 9 cm deep). The pale yellow ethyl acetate layer was separated and evaporated in vacuo to dryness in a rotary evaporator to yield approximately 7.2 g of Residue A.

Liquid-Liquid Partition of Residue A:

5 Residue A (7.2 g) was dissolved in 100 ml of 10% water in methanol. The solution was transferred to a separatory funnel and extracted 4 times with an equal volume of hexane. The hexane layer was removed. The aqueous methanol phase was diluted to 35% water in methanol by adding 38 ml of water and extracted 3 times with an equal volume of chloroform. The chloroform had been previously saturated
10 with 35% water in methanol. The hexane, chloroform, and aqueous methanol extracts were evaporated to dryness in vacuo in a rotary evaporator. The nocathiacin antibiotics were concentrated primarily in the chloroform fraction, (Residue B, 1.3 g).

15

Sephadex LH-20 Chromatography of Residue B:

Residue B (1.3 g) was dissolved in 10 ml chloroform-methanol 1:1 and applied to a 3 x 100 cm Glenco column packed with 100 g Sephadex
20 LH-20 in chloroform-methanol 1:1. After a 75 ml forerun, fractions measuring 8-10 ml each were collected at a flow rate of 2-3 ml/min. Fractions were consolidated on the basis of silica TLC profiles (chloroform-methanol 9:1, long wavelength UV and/or ceric sulfate spray). In this manner, the yellow fluorescent nocathiacin antibiotic
25 complex was detected in fractions 10-15. The fractions were combined and evaporated to dryness, (Residue C, 284 mg).

Silica Gel Vacuum Liquid Chromatography of Residue C:

30 The nocathiacin antibiotic enriched fraction (Residue C) was preadsorbed onto 2 g Merck LiChroprep Silica Gel 60 (25-40 μ) and applied

to a 2.5 x 15 cm fritted filter funnel packed half full with this adsorbent. Elution using house vacuum was initially with hexane-chloroform 1:1 (100 ml), followed by chloroform, and increasing percentages of methanol in chloroform (e.g. 2.5, 5, 7.5, 10, 12.5, 15, and 25% methanol in chloroform (100 ml each). Fractions were consolidated on the basis of silica TLC profiles (chloroform-methanol 9:1, long wavelength UV and ceric sulfate spray). In this manner, nocathiacin I was detected in the 5% through 12.5% methanol in chloroform fractions. Nocathiacin II was detected in the 15% through 25% methanol in chloroform fractions. Like fractions were combined and evaporated to dryness, (Residue D, nocathiacin I, 230 mg), (Residue E, nocathiacin II, 49 mg.)

Isolation of Nocathiacin I and II:


Residues D and E were further purified using the specified Beckman System Gold preparative HPLC system. A typical sample injection size was 25-50 mg/50-100 µl DMSO. Elution was begun with chloroform with a pre-programmed concave gradient to chloroform-methanol 8:2 over a 30 minute period. Elution flow rate was 10 ml/min. Detection (UV) was at 290 nm. In this manner, nocathiacin I (17 min peak, 56 mg total yield) and nocathiacin II (19.5 min peak, 6.7 mg total yield) were obtained.

Purification Scheme

The following scheme depicts the purification of nocathiacin antibiotics:

PURIFICATION OF NOCATHIACINS I AND II
(Example 1, From Fermentation in Shake Flasks)

Fermentation Broth (*Nocardia* sp.)



Physico-Chemical Properties of Nocathiacin I

	Description:	pale-yellow amorphous solid
5	Molecular Formula:	$C_{61}H_{60}N_{14}O_{18}S_5$
	Molecular Weight:	1436
10	Mass Spectrum:	HR-ESIMS $[M+H]^+$ m/z 1437.285 ESI-MS/MS fragmentation ions: m/z 1266, 1248, 1221, 1204, 1186, 1154, 788
15	Infrared Spectrum:	Major IR Bands (cm^{-1}) 3392, 3108, 2932, 1740, 1721, 1694, 1670, 1640, 1533, 1478, 1420, 1384, 1320, 1250, 1207, 1128, 1091, 1037, 1014, 751.
	Ultraviolet Spectrum:	λ_{max} (MeOH) 222, 290, 364 nm (log ϵ 4.89, 4.52, 4.17)
20	Circular Dichroism:	CD λ nm ($\Delta\epsilon$) (MeOH) 212 (+34.1), 239 (-50.5), 267 (+20.8), 307 (-8.7), 364 (+5.5)
25	HPLC (Rt)	25.6 min; (C18; Acetonitrile - 0.01M potassium phosphate buffer pH 3.5 gradient (J. Chromatogr. 385, 99 (1987))).
30	1H -NMR	Observed Chemical Shifts (relative to DMSO- d_6 signal δ 2.49): δ 10.05 (1H, s), 9.07 (1H, s), 8.65 (1H, s), 8.57 (1H, d, J=8.0 Hz), 8.51 (1H, s), 8.50 (1H, s), 8.24 (1H, s),

22

8.07 (1H, s br), 7.89 (1H, d, J=11.2 Hz), 7.86 (2H, s),
 7.70 (1H, d, J=8.4 Hz), 7.61 (1H, s br), 7.34 (2H, m),
 7.16 (1H, d, J=6.9 Hz), 6.40 (1H, s), 5.98 (1H, d,
 J=12.0 Hz), 5.77 (1H, s), 5.73 (1H, dd, J=10.9, 4.4
 Hz), 5.70 (1H, d, J=8.7 Hz), 5.22 (1H, m), 5.02 (1H,
 d, J=11.4 Hz), 4.94 (1H, d, J=3.7 Hz), 4.75 (1H, d,
 J=10.2 Hz), 4.51 (1H, d, J=11.0 Hz), 4.29 (1H, d,
 J=9.6 Hz), 4.19 (1H, m), 4.13 (1H, d, J=10.1 Hz),
 4.00 (1H, d, J=9.5 Hz), 3.88 (3H, s), 3.78 (1H, d br,
 J=5.9 Hz), 2.52 (6H, s), 2.49 (1H, m), 2.11 (1H, s br),
 1.99 (3H, s), 1.95 (1H, m), 1.81 (1H, d, J=13.9 Hz),
 1.43 (3H, s), 1.21 (1H, m), 1.16 (3H, s, br), 0.59 (3H,
 d, J=6.3 Hz).

15 ¹³C-NMR

Observed Chemical Shifts (relative to DMSO-d₆
 signal δ 39.6):

δ 171.8, 168.1, 167.7, 167.4, 167.0, 165.2, 164.0,
 163.1, 161.5, 161.1, 160.5, 160.3, 159.1, 158.6, 154.6,
 151.9, 149.7, 149.6, 148.8, 145.8, 142.5, 135.3, 135.0,
 134.5, 129.9, 128.1, 127.0, 126.3, 125.5, 124.0, 123.1,
 119.8, 119.4, 112.7, 111.2, 109.7, 103.7, 95.1, 79.3,
 70.6, 68.4, 67.5, 66.1, 65.1, 64.5, 63.3, 56.1, 55.5, 50.2,
 49.8, 44.4, 40.0, 30.5, 18.0, 13.1.

25

Physico-Chemical Properties of Nocathiacin II

Description: pale-yellow amorphous solid

30 Molecular Formula: C₆₁H₆₀N₁₄O₁₇S₅

	Molecular Weight:	1420
5	Mass Spectrum:	HR-ESIMS [M+H] ⁺ m/z 1421.297 ESI-MS/MS fragmentation ions: m/z 1250, 1206, 1188, 1170, 1156, 1138, 788
10	Infrared Spectrum:	Major IR Bands (cm ⁻¹) 3387, 1725, 1656, 1534, 1478, 1423, 1318, 1249, 1192, 1087, 1014, 886, 793, 751.
	Ultraviolet Spectrum:	λ_{max} (MeOH) 220, 295, 364 nm (log ϵ 5.01, 4.67, 4.36)
15	Circular Dichroism:	CD λ nm ($\Delta\epsilon$) (MeOH) 211 (+41.5), 235 (-56.1), 258 (+21.0), 277 (+13.4), 307 (-10.0), 364 (+5.6)
20	HPLC (Rt)	21.1 min; (C18; Acetonitrile - 0.01M potassium phosphate buffer pH 3.5 gradient (J. Chromatogr. 385, 99 (1987))).
25	¹ H-NMR	Observed Chemical Shifts (relative to DMSO-d ₆ signal δ 2.49): δ 9.10 (1H, s), 8.59 (1H, d, J=8.5 Hz), 8.51 (1H, s), 8.45 (1H, s), 8.22 (1H, s), 8.15 (1H, s), 8.05 (1H, s br), 7.69 (1H, s br), 7.66 (1H, s), 7.51 (1H, d, J=8.3 Hz), 7.47 (1H, s), 7.30 (1H, s), 7.25 (1H, dd, J=8.0, 7.2 Hz), 7.12 (1H, d, J=7.1 Hz), 7.02 (1H, d, J=8.4 Hz), 6.49 (1H, s), 6.03 (1H, d, J=12.1 Hz), 5.78 (1H, m), 5.70 (1H, d, J=8.6 Hz), 5.66 (1H, s), 5.30 (1H, d, J=7.7 Hz), 5.00 (1H, d, J=13.0 Hz), 4.98 (1H, d,
30		

5 J=10.5 Hz), 4.94 (1H, d, J=4.8 Hz), 4.83 (1H, d, J=11.2 Hz), 4.72 (1H, m), 4.37 (1H, d, J=9.6 Hz), 4.23 (1H, m), 4.11 (1H, d, J=9.9 Hz), 4.03 (1H, d, J=7.7 Hz), 3.89 (3H, s), 3.75 (1H, m), 2.49 (6H, s), 2.14 (1H, m), 2.01 (3H, s), 1.94 (1H, m), 1.79 (1H, d, J=14.2 Hz), 1.40 (3H, s), 1.23 (1H, m), 1.04 (3H, s, br), 0.54 (3H, d, J=6.5 Hz).

10 ¹³C-NMR Observed Chemical Shifts (relative to DMSO-d₆ signal δ 39.6):
 δ 172.0, 168.2, 167.1, 167.0, 165.5, 165.3, 163.2, 162.9, 161.6, 161.2, 160.6, 160.1, 158.7, 156.3, 149.9, 149.0, 148.2, 145.9, 138.8, 136.9, 134.3, 128.8, 127.9, 127.2, 126.6, 125.6, 125.2, 124.7, 124.1, 123.9, 122.8, 117.9, 116.3, 115.6, 109.9, 101.9, 95.1, 79.0, 70.7, 68.4, 67.6, 66.3, 66.0, 64.0, 62.5, 56.1, 55.1, 51.4, 50.6, 44.4, 40.5, 30.6, 18.1, 18.0, 13.0.

15

20 BIOLOGICAL EVALUATION OF NOCATHIACIN ANTIBIOTICS

EXAMPLE 2: Antibiotic Activity of Nocathiacin I and II

25 To demonstrate its antimicrobial properties, the minimum inhibitory concentration (MIC) for nocathiacin antibiotics of the invention was obtained against a variety of bacteria using a conventional broth dilution assay (serial broth dilution method using nutrient broth (Difco)). The results obtained are shown in Table 1 below, and demonstrate that nocathiacins have utility in treating bacterial infections.

Table 1.

Organism	Strain #	MIC (ug/ml)	
		Nocathiacin I	Nocathiacin II
<i>Streptococcus pneumoniae</i>	A9585	0.001	0.015
<i>Streptococcus pneumoniae</i> /penicillin intermediate	A27881	0.001	0.015
<i>Streptococcus pneumoniae</i> /penicillin resistant	A28272	0.001	0.015
<i>Streptococcus pyogenes</i>	A9604	0.001	0.125
<i>Enterococcus faecalis</i>	A20688	0.03	0.5
<i>Enterococcus faecalis</i>	A27519	0.03	0.5
<i>Enterococcus faecalis</i> +50% calf serum	A20688	0.25	0.5
<i>Enterococcus faecium</i>	A24885	0.015	0.5
<i>Enterococcus faecium</i> /thiostrepton resistant (10 ug/ml)	SC15829	0.125	0.5
<i>Enterococcus avium</i>	A27456	0.015	0.5
<i>Staphylococcus aureus</i>	A9537	0.001	0.06
<i>Staphylococcus aureus</i> /β-lactamase positive	A15090	0.007	0.5
<i>Staphylococcus aureus</i> + 50% calf serum	A15090	0.015	0.5
<i>Staphylococcus aureus</i> /QC/ATCC#29213	A24407	0.007	0.5
<i>Staphylococcus aureus</i> /hetero methicillin resistant	A27218	0.003	0.5
<i>Staphylococcus aureus</i> + 50% calf serum	A27218	0.007	0.5
<i>Staphylococcus aureus</i> /homo methicillin resistant	A27223	0.003	0.125

26

Staphylococcus aureus + 50% calf serum	A27223	0.001	0.125
Micrococcus luteus	A9852	0.003	0.125
Bacillus subtilis	A9506A	0.001	0.125
Staphylococcus epidermidis	A24548	0.003	0.125
Staphylococcus haemolyticus	A27298	0.03	0.25
Escherichia coli	A15119	>128	>128
Escherichia coli	A22292	>128	>128
Escherichia coli/AcrA::Kan	A28901	>128	>128
Salmonella enteritidis	A9531	>128	>128
Moraxella catarrhalis/ β - lactamase positive	A22344	0.06	0.125
Moraxella catarrhalis/ β - lactamase positive	A25409	0.06	0.125
Haemophilus influenzae/ β -lactamase negative	A20191	>128	
Haemophilus influenzae/ β -lactamase negative	A20183	>128	
Haemophilus influenzae/ β -lactamase positive	A21515	>128	
Salmonella/WT	A27207	>128	>128
Salmonella/RE	A27208	>128	>128

EXAMPLE 3: Nocathiacin I *in vivo* Antibiotic Activity in a Systemic *Staph. aureus* Infection Model.

5

Nocathiacin I was evaluated for antibiotic activity *in vivo*, in a systemic infection model using female ICR mice. The animals were

infected IP with 6.5×10^6 CFU of an overnight culture of *Staphylococcus aureus* A15090 suspended in 7% mucin. Nocathiacin I was dissolved in a test formulation consisting of 10% DMSO, 5% Tween 80 and 85% water. The solution was administered subcutaneously at 100 mg/kg total dose (2 x 50 mg/kg doses at 1 and 4 hours post-infection). Nine out of nine animals survived the duration of the experiment with no signs of toxicity. The PD_{50} of nocathiacin I was determined to be <6.25 mg/kg.

NOCATHIACIN III PREPARED BY FERMENTATION

10

Production of nocathiacin III can be effected at any temperature conducive to satisfactory growth of the producing organism, e.g. 16°C and 40°C, but it is preferable to conduct the fermentation at 22°C to 26°C. The aqueous medium is incubated for a period of time necessary to complete the production of nocathiacin III as monitored by high pressure liquid chromatography (HPLC) usually for a period of about 1-5 days, on a rotary shaker operating at about 50 rpm to 300 rpm, preferably at 150 to 200 rpm.

The product, nocathiacin III, can be recovered from the culture medium by conventional means which are commonly used for the recovery of other known biologically active substances. Nocathiacin III can be obtained upon extraction of the culture with a conventional solvent, such as ethyl acetate, treatment with a conventional resin (e.g. anion or cation exchange resin, non-ionic adsorption resin), treatment with a conventional adsorbent (e.g. activated charcoal, silica gel, cellulose, alumina), crystallization, recrystallization, and/or purification by reverse phase preparative HPLC.

The following examples set out the preparation of nocathiacin III by fermentation. Reasonable variations, such as those which would occur to

a skilled artisan can be made herein without departing from the scope of the invention.

Fermentation

5

EXAMPLE 4:

From the frozen vegetative stock culture of *Nocardia* sp. ATCC-202099, 4 ml was used to inoculate 100 ml of seed medium contained the following per liter of deionized water: Japanese soluble starch, 20 g; Dextrose, 5 g; N-Z case, 3 g; yeast extract, 2 g; fish meat extract, 5 g; calcium carbonate 3 g, in a 500-ml flask. The culture was incubated at 28°C on a rotary shaker operating at 250 rpm for 3 days. Four ml of the resulting culture was used to inoculate each of ten 500-ml flasks containing the 100 ml of producing medium consisting of the following per liter of deionized water: HY yeast 412, 10 g; Dextrose, 20 g; Nutrisoy, 10 g. The producing cultures were incubated at 28°C on a rotary shaker operating at 250 rpm for 2 days. The cultures were then processed for the recovery of the nocathiacin III.

20

EXAMPLE 5:

From the frozen vegetative stock culture of *Nocardia* sp. ATCC-202099, 4 ml was used to inoculate 100 ml of seed medium contained the following per liter of deionized water: Japanese soluble starch, 20 g; Dextrose, 5 g; N-Z case, 3 g; yeast extract, 2 g; fish meat extract, 5 g; calcium carbonate 3 g, in a 500-ml flask. The culture was incubated at 28°C on a rotary shaker operating at 250 rpm for 3 days. Four ml of the resulting culture was added to each of five 500-ml flasks containing the 100 ml of fresh seed medium and the culture was incubated at 28°C on a rotary shaker operating at 250 rpm for 3 days. The resulting culture from five

flasks was pooled and 4 ml of the combined culture was used to inoculate each of one hundred 500-ml flasks containing the 100 ml of producing medium consisting of the following per liter of deionized water: HY yeast 412, 10 g; Dextrose, 20 g; Nutrisoy, 10 g. The producing cultures were
5 incubated at 24°C on a rotary shaker operating at 180 rpm for 4 days. The cultures were then processed for the recovery of the nocathiacin III.

EXAMPLE 6: Isolation of Nocathiacin III

10

Preparation of Crude Extract:

Fermentation broth of *Nocardia* sp. ATCC-202099 (1.2 L.) was extracted (whole broth including mycelia) with approximately 1 L. ethyl
15 acetate by vigorous shaking. The biphasic mixture was centrifuged and the phases separated. The aqueous portion was extracted again with ethyl acetate (0.5 L.). The pale yellow ethyl acetate extracts were pooled and evaporated in vacuo to dryness in a rotary evaporator to yield approximately 198 mg of Residue A.

20

Liquid-Liquid Partition of Residue A:

Residue A (198 mg) was dissolved in 10 ml of 10% water in methanol. The solution was transferred to a separatory funnel and
25 extracted 3 times with an equal volume of hexane. The hexane layer was removed. The aqueous methanol phase was diluted to 35% water in methanol by adding 3.8 ml of water and extracted 3 times with an equal volume of chloroform. The chloroform had been previously saturated with 35% water in methanol. The hexane, chloroform, and aqueous
30 methanol extracts were evaporated to dryness in vacuo in a rotary evaporator. Nocathiacin antibiotics were detected primarily in the chloroform fraction, (Residue B, 106 mg).

Isolation of Nocathiacin III:

Residue B was further purified using the specified Beckman System Gold preparative HPLC system; YMC ODS-AQ C18 column. A typical sample injection size was 50 mg/250 μ l DMSO. Elution was begun with 0.1M ammonium acetate-acetonitrile 55:45 v/v with a 30 minute linear gradient to acetonitrile. Elution flow rate was 10 ml/min. Detection (UV) was at 360 nm. In this manner, nocathiacin III (9 minute peak, 12 mg total yield) was obtained.

Physico-Chemical Properties of Nocathiacin III

15	Description:	buff amorphous solid
	Molecular Formula:	$C_{52}H_{43}N_{13}O_{16}S_5$
	Molecular Weight:	1265
20	Mass Spectrum:	HR-ESIMS $[M+H]^+$ m/z 1266.162 ESI-MS/MS fragmentation ions: m/z 1248, 1222, 1204, 1186, 788
25	Infrared Spectrum:	Major IR Bands (cm^{-1}) 3382, 1720, 1667, 1643 sh, 1534, 1510, 1477, 1420, 1250, 1207, 1126, 1015, 750.
	Ultraviolet Spectrum:	λ_{max} (MeOH) nm 224, 290, 364 (log ϵ 4.85, 4.52, 4.11).
30	Circular Dichroism:	CD λ nm ($\Delta\epsilon$) (MeOH) 212 (+38.7), 238 (-47.6), 266 (+21.2), 305 (-11.4), 362 (+5.1).

	HPLC (Rt)	19.3 min; (C18; Acetonitrile - 0.01M potassium phosphate buffer pH 3.5 gradient (J. Chromatogr. 385, 99 (1987))).
5	¹ H-NMR	Observed Chemical Shifts (relative to DMSO-d ₆ signal δ 2.49):
10		δ 10.05 (1H, s), 8.93 (1H, s), 8.59 (1H, s), 8.51 (1H, s), 8.46 (1H, s), 8.37 (1H, d, J=8.9 Hz), 8.20 (1H, s), 8.05 (1H, s), 7.91 (1H, d, J=10.9 Hz), 7.77 (1H, s br), 7.74 (1H, s br), 7.69 (1H, d, J=8.4 Hz), 7.60 (1H, s), 7.38 (1H, d, J=7.5 Hz), 7.34 (1H, dd, J=8.2, 7.2 Hz), 7.18 (1H, d, J=7.0 Hz), 6.37 (1H, s), 6.07 (1H, d, J=7.1 Hz), 5.92 (1H, d, J=12.2 Hz), 5.89 (1H, d, J=10.3 Hz), 5.74 (1H, dd, J=10.8, 4.8 Hz), 5.72 (1H, s), 5.24 (1H, m), 5.02 (1H, d, J=12.5 Hz), 4.71 (1H, d, J=10.4 Hz), 4.54 (1H, d, J=11.2 Hz), 4.50 (1H, m), 4.20 (1H, m), 4.13 (1H, d, J=10.4 Hz), 4.02 (1H, dd, J=9.4, 7.2 Hz), 3.87 (3H, s), 3.73 (1H, d, J=9.6 Hz), 1.97 (3H, s), 1.15 (3H, s br).
15		
20	¹³ C-NMR	Observed Chemical Shifts (relative to DMSO-d ₆ signal δ 39.6):
25		δ 174.5, 172.2, 168.1, 167.8, 166.6, 165.3, 164.4, 163.0, 161.2, 160.4, 159.3, 158.8, 154.7, 152.9, 149.6, 148.8, 146.0, 141.6, 135.7, 135.0, 134.5, 129.9, 128.6, 127.1, 126.4, 126.3, 125.6, 125.3, 124.2, 123.1, 119.7, 119.5, 112.5, 111.3, 109.8, 103.7, 81.4, 67.9, 67.3, 65.3, 64.5, 63.5, 56.2, 55.7, 49.7, 49.5, 18.0, 13.2.
30		

EXAMPLE 7: Antibiotic Activity of Nocathiacin III

To demonstrate its antimicrobial properties, the minimum inhibitory concentration (MIC) for the nocathiacin III antibiotic of this invention was obtained against a variety of bacteria using a conventional broth dilution assay (serial broth dilution method using nutrient broth (Difco)). The results obtained are shown in Table 2 below, and demonstrate that nocathiacin III has utility in treating bacterial infections.

10 Table 2.

Organism	Strain #	MIC (ug/ml)
		Nocathiacin III
<i>Streptococcus pneumoniae</i>	A9585	≤ 0.002
<i>Streptococcus pneumoniae</i> /penicillin intermediate	A27881	≤ 0.002
<i>Streptococcus pneumoniae</i> /penicillin resistant	A28272	≤ 0.002
<i>Enterococcus faecalis</i>	A20688	0.03
<i>Enterococcus faecalis</i>	A27519	0.03
<i>Enterococcus faecalis</i> +50% calf serum	A20688	0.25
<i>Enterococcus faecium</i>	A24885	0.03
<i>Enterococcus avium</i>	A27456	0.03
<i>Staphylococcus aureus</i> /β-lactamase positive	A15090	0.007
<i>Staphylococcus aureus</i> + 50% calf serum	A15090	0.03
<i>Staphylococcus aureus</i> /QC/ATCC#29213	A24407	0.007


33

Staphylococcus aureus /homo methicillin resistant	A27223	0.007
Staphylococcus aureus + 50% calf serum	A27223	0.007
Staphylococcus epidermidis	A24548	0.007
Staphylococcus haemolyticus	A27298	0.007
Moraxella catarrhalis/ β - lactamase positive	A22344	0.06
Moraxella catarrhalis/ β - lactamase positive	A25409	0.06
Haemophilus influenzae/ β -lactamase negative	A20191	>64
Haemophilus influenzae/ β -lactamase negative	A20183	>64
Haemophilus influenzae/ β -lactamase positive	A21515	>64

CLAIMS


What is claimed is:

- 5 1. A nocathiacin compound, or a pharmaceutically acceptable salt thereof having the formula



- 10** **wherein:**

R is H or OH;



2. The compound of claim 1 selected from the group consisting of nocathiacin I, II and III, or a pharmaceutically acceptable salt thereof;

wherein nocathiacin I has the following characteristics:

5

(a) appears as a pale-yellow amorphous solid;

(b) has a molecular weight of 1436 as determined by mass spectrometry;

10

(c) has the molecular formula $C_{61}H_{60}N_{14}O_{18}S_5$

(d) exhibits an ultraviolet absorption spectrum when dissolved in methanol substantially as shown in FIG. 1;

15

(e) exhibits an infrared absorption spectrum (KBr) substantially as shown in FIG 2;

20

(f) when dissolved in deuterated dimethylsulfoxide exhibits a proton magnetic resonance spectrum substantially as shown in FIG. 3;


(g) when dissolved in deuterated dimethylsulfoxide exhibits a ^{13}C magnetic resonance spectrum substantially as shown in FIG. 4;

25

(h) exhibits a high performance liquid chromatography retention time of 25.6 minutes with a C18 reversed phase silica gel column using a 0.01M potassium phosphate buffer pH 3.5 - acetonitrile gradient;

30

(i) and has the formula



;


wherein nocathiacin II has the following characteristics:

5

- (a) appears as a pale-yellow amorphous solid;
- (b) has a molecular weight of 1420 as determined by mass spectrometry;
- (c) has the molecular formula $C_{61}H_{60}N_{14}O_{17}S_5$
- (d) exhibits an ultraviolet absorption spectrum when dissolved in methanol substantially as shown in FIG. 5;
- (e) exhibits an infrared absorption spectrum (KBr) substantially as shown in FIG 6;

15

- (f) when dissolved in deuterated dimethylsulfoxide exhibits a proton magnetic resonance spectrum substantially as shown in FIG. 7;
- 5 (g) when dissolved in deuterated dimethylsulfoxide exhibits a ^{13}C magnetic resonance spectrum substantially as shown in FIG. 8;
- (h) exhibits a high performance liquid chromatography retention time of 21.1 minutes with a C18 reversed phase silica gel column
 10 using a 0.01M potassium phosphate buffer pH 3.5 - acetonitrile gradient;
- (i) and has the formula




15

and wherein nocathiacin III has the following characteristics:

- (a) appears as a buff colored amorphous solid;


- (b) has a molecular weight of 1265 as determined by mass spectrometry;
- 5 (c) has the molecular formula $C_{52}H_{43}N_{13}O_{16}S_5$
- (d) exhibits an ultraviolet absorption spectrum when dissolved in methanol substantially as shown in FIG. 9;
- 10 (e) exhibits an infrared absorption spectrum (KBr) substantially as shown in FIG 10;
- (f) when dissolved in deuterated dimethylsulfoxide exhibits a proton magnetic resonance spectrum substantially as shown in
15 FIG. 11;
- (g) when dissolved in deuterated dimethylsulfoxide exhibits a ^{13}C magnetic resonance spectrum substantially as shown in FIG. 12;
- 20 (h) exhibits a high performance liquid chromatography retention time of 19.3 minutes with a C18 reversed phase silica gel column using a 0.01M potassium phosphate buffer pH 3.5 - acetonitrile gradient;
- 25 (i) and has the formula

39



3. A compound of claim 1 which is nocardiacin I.
- 5 4. A compound of claim 1 which is nocardiacin II.
5. A compound of claim 1 which is nocardiacin III.
- 10 6. A pharmaceutical composition comprising a therapeutically effective amount of a compound as claimed in any of claims 1-5 and a suitable carrier or diluent.
7. A method for preventing or treating infection of a mammal by a
15 bacterium, comprising the step of administering a therapeutically effective amount of a compound as claimed in any of claims 1-5 to said mammal in need thereof.
8. A biologically pure culture of the microorganism *Nocardia* sp.
20 (ATCC-202099).

9. A method of making a compound as claimed in any of claims
1-5 comprising the steps of fermenting the microorganism *Nocardia* sp.
(ATCC-202099) and isolating nocathiacin I, II and III antibiotics from the
5 fermentation broth.

**FIG. 1**






FIG. 2



**FIG. 4**




FIG. 5





FIG. 6

**FIG. 7**





FIG. 8

**FIG. 9**





FIG. 10

**FIG. 11**




FIG. 12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/15776

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/71

US CL :514/9; 530/317; 435/713, 253.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/9; 530/317; 435/713, 253.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	SASAKI et al. MJ347-81F4 A & B, Novel Antibiotics from Amycolatopsis sp.: Taxonomic Characteristics, Fermentation, and Antimicrobial Activity. Journal of Antibiotics. 25 August 1998, Vol. 51, No. 8, pages 715-721, especially Figure 1, page 716.	1-3

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 SEPTEMBER 1999

Date of mailing of the international search report

14 OCT 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FIONA T. POWERS

Telephone No. (703) 308-1235

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRIX

